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Letters to the Editors
Appearance of rheumatoid 
nodules following anti-tumor 
necrosis factor α treatment with 
adalimumab for rheumatoid 
arthritis
Sirs, 
The increasing use of tumor necrosis fac-
tor α (TNF-α) antagonists in the treatment 
of inflammatory rheumatic disorders, while 
driving a remarkable clinical improvement 
for many patients, has raised concerns on 
possible side effects. Among these, a few 
cases of rheumatoid nodules formation 
following treatment with etanercept have 
been signalled (1-3), approaching previous 
descriptions related to DMARDs therapy 
(4-7).
We report a case of a 45 year-old Caucasian 
woman affected by rheumatoid arthritis 
(RA) who developed rheumatoid nodules 
while taking adalimumab. The patient was 
diagnosed as having RA in 1997 and treated 
with several DMARDs in association with 
low-dose corticosteroids and nonsteroidal 
anti-inflammatory drugs. She was referred 
to our rheumatology division in September 
2002: erosive polyarthritis involving wrists, 
hands and feet, positivity of rheumatoid fac-
tor, and increased values of ESR (58 mm/1st 
hr) and CRP (12 mg/L) were demonstrated. 
In March 2003, the patient was started on 
adalimumab 40 mg subcutaneously every 
other week, with add-on prednisone and ox-
aprozin obtaining prompt clinical and labo-
ratory (ESR 36 mm/1st hr; CRP 0.5 mg/L) 
improvement. In October 2005, the patient 
experienced again a polyarticular flare and 
elevated ESR and CRP values. Moreover, 
she complained of the appearance of sub-
cutaneous nodules in the extensor side of 
the elbows starting five months before. The 
ultrasonographic assessment, using a high 
resolution linear probe, showed changes 
suggestive of rheumatoid nodules, charac-
terized by hypoechoic formations with a 
round shape and well defined margins per-
mitting a good definition from the nearby 
tissues (Fig. 1). The dosing frequency of 
adalimumab was augmented to 40 mg 
subcutaneously every week. Two months 
later the size and number of the nodules 
remained unchanged, as confirmed by ul-
trasound assessment, while the articular 
involvement worsened (ESR 90 mm/1st hr; 
CRP 9 mg/L). 
Rheumatoid nodules are considered as 
the most characteristic extra-articular his-
topathological lesion in RA, usually asso-
ciated with a more severe disease (8). The 
pathogenetic mechanism is still unknown, 
but vasculitis is deemed as one of the most 
suitable, since endothelial cell injury, fa-
voured by complement activation and im-
munoglobulin deposition, is an essential 
component of both early and long-standing 
nodules (9). The main infiltrating inflam-
matory cell inside the rheumatoid nodule 
is the macrophage, which is also the ma-
jor cell producing TNF-α (8). Rheumatoid 
nodule formation has been described fol-
lowing treatment with etanercept, a recom-
binant TNF-α receptor fusion protein. Our 
case represents the first description of the 
appearance of such nodules after the intro-
duction of adalimumab, an anti-TNF-α hu-
man monoclonal antibody. In the previous 
reports the emergence of nodules ranged 
from eight weeks to seventeen months af-
ter the commencement of etanercept (1-3), 
while our patient developed nodulosis after 
two years of adalimumab treatment. The 
new formation of nodules may be a benign 
side effect of treatment, resulting from in-
creased cell death and enhanced chemo-
taxis of inflammatory cells by the enlarging 
necrotic centre of the rheumatoid nodule 
(2). Indeed, in vitro models have demon-
strated that adalimumab is capable to lyse 
surface TNF-expressing cells in the pres-
ence of complement (10) and the activation 
of complement has been largely document-
ed within the rheumatoid nodule. Other-
wise, rheumatoid nodules may represent 
the expression of a chronic inflammation, 
less susceptible to TNF-α blockers (2), due 
to the lower TNF-α concentrations com-
pared with the synovium (8). Undoubtedly 
our patient presented predisposing factors 
for the development of nodulosis, including 
a longstanding disease with severe articular 
involvement and rheumatoid factor posi-
tivity; yet, she did not exhibit the nodules 
until the treatment with adalimumab was 
introduced. 
Surely further studies are needed to bet-
ter define the relationship between TNF-α 
blockade and the appearance of these typi-
cal extra-articular manifestations of RA.
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Fig. 1. Posterior transverse ultrasound scan of the right elbow of the patient: the hypoechoic formation in the subcu-
taneous region is suggestive of a rheumatoid nodule.
